Patents by Inventor Scott Albert Uhland

Scott Albert Uhland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10328203
    Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 25, 2019
    Assignee: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Scott Albert Uhland, Eric Peeters, Bryan Thomas Preas, Joerg Martini
  • Publication number: 20170035970
    Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Inventors: SCOTT ALBERT UHLAND, ERIC PEETERS, BRYAN THOMAS PREAS, JOERG MARTINI
  • Patent number: 9480795
    Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 1, 2016
    Assignee: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Scott Albert Uhland, Eric Peeters, Bryan Thomas Preas, Joerg Martini
  • Patent number: 8642830
    Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: February 4, 2014
    Assignee: Palo Alto Research Center Incorporated
    Inventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
  • Patent number: 8317749
    Abstract: A method of enabling administration of a drug includes determining, within a drug-transfer device including cells, a location of at least one cell and generating information identifying the determined location. A user may be provided with the drug-transfer device. The drug is retained within the at least one cell when the user is provided with the drug-transfer device. The method also includes encoding a key with the information and providing the user with the key before, after or when the user is provided with the drug-transfer device. Drug retained within the at least one cell is selectively releasable when the key is operably proximate to the drug-transfer device and is encoded with the information. The key can be encoded with the information before and/or after being provided to the user. In some embodiments, the key is encoded based on instructions transmitted over a network.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: November 27, 2012
    Assignee: Palo Alto Research Center Incorporated
    Inventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
  • Patent number: 8313456
    Abstract: Devices capable of deterring or preventing bulk extraction of drugs from, for example, drug-delivery systems are exemplarily disclosed. In one embodiment, such a device may include a package releasably retaining a drug and an agent. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The cell package is configured such that an amount of the drug is selectively releasable with respect to the agent when the package is operably proximate to an encoded key. The package, however, may be configured to impose a relatively high likelihood that either the drug will not be accessed or the drug will be contaminated by the agent if access to the contents of the package is sought without the use of an encoded key.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: November 20, 2012
    Assignee: Palo Alto Research Center Incorporated
    Inventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
  • Publication number: 20120277514
    Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.
    Type: Application
    Filed: July 3, 2012
    Publication date: November 1, 2012
    Applicant: Palo Alto Research Center Incorporated
    Inventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
  • Publication number: 20120248092
    Abstract: A thermistor has a mixture of a temperature sensitive material and a conductive material, and an electrode in electrical contact with the mixture. A method of manufacturing a thermistor includes depositing conductive contacts onto a substrate, printing a thermistor mixture of temperature sensitive material and a conductive material over the contact, and annealing the thermistor mixture to produce a flexible thermistor on the conductive contacts.
    Type: Application
    Filed: March 30, 2011
    Publication date: October 4, 2012
    Applicant: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Scott Albert Uhland, Jurgen H. Daniel, Gregory Lewis Whiting
  • Patent number: 8257736
    Abstract: A method of fabricating a drug-transfer device includes forming a package having a first component retaining multiple volumes of a drug and a second component retaining an agent. The first component and the second component are integrally formed together. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The method allows exterior surfaces of the first and second components to be cleanable (e.g., prior to final assembly). After such cleaning, either no or substantially no amount of drug and agent is present outside the package. According to some embodiments, the package may be fabricated such that either no or substantially no amount of the drug is present within the second component and such that either no or substantially no amount of the agent is present within the first component.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: September 4, 2012
    Assignee: Palo Alto Research Center Incorporated
    Inventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
  • Patent number: 8236238
    Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: August 7, 2012
    Assignee: Palo Alto Research Center Incorporated
    Inventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
  • Publication number: 20100331772
    Abstract: Devices capable of deterring or preventing bulk extraction of drugs from, for example, drug-delivery systems are exemplarily disclosed. In one embodiment, such a device may include a package releasably retaining a drug and an agent. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The cell package is configured such that an amount of the drug is selectively releasable with respect to the agent when the package is operably proximate to an encoded key. The package, however, may be configured to impose a relatively high likelihood that either the drug will not be accessed or the drug will be contaminated by the agent if access to the contents of the package is sought without the use of an encoded key.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 30, 2010
    Applicant: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
  • Publication number: 20100326020
    Abstract: A method of fabricating a drug-transfer device includes forming a package having a first component retaining multiple volumes of a drug and a second component retaining an agent. The first component and the second component are integrally formed together. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The method allows exterior surfaces of the first and second components to be cleanable (e.g., prior to final assembly). After such cleaning, either no or substantially no amount of drug and agent is present outside the package. According to some embodiments, the package may be fabricated such that either no or substantially no amount of the drug is present within the second component and such that either no or substantially no amount of the agent is present within the first component.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 30, 2010
    Applicant: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
  • Publication number: 20100328024
    Abstract: A method of enabling administration of a drug includes determining, within a drug-transfer device including cells, a location of at least one cell and generating information identifying the determined location. A user may be provided with the drug-transfer device. The drug is retained within the at least one cell when the user is provided with the drug-transfer device. The method also includes encoding a key with the information and providing the user with the key before, after or when the user is provided with the drug-transfer device. Drug retained within the at least one cell is selectively releasable when the key is operably proximate to the drug-transfer device and is encoded with the information. The key can be encoded with the information before and/or after being provided to the user. In some embodiments, the key is encoded based on instructions transmitted over a network.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 30, 2010
    Applicant: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Philipp Helmut Schmaelzle, Scott Albert Uhland
  • Patent number: 7838715
    Abstract: A drug deactivation system according to some embodiments includes at least one degradable capsule exposed to at least one drug-retaining region of a drug delivery device and an agent. The agent is configured to render a drug ineffective upon degradation of the at least one capsule. The at least one drug-retaining region is configured to retain one of the drug and the agent and the at least one capsule is configured to retain the other of the drug and the agent.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 23, 2010
    Assignee: Palo Alto Research Center Incorporated
    Inventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
  • Publication number: 20100185143
    Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 22, 2010
    Applicant: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Scott Albert Uhland, Eric Peeters, Bryan Thomas Preas, Joerg Martini
  • Publication number: 20100185038
    Abstract: A drug deactivation system according to some embodiments includes at least one degradable capsule exposed to at least one drug-retaining region of a drug delivery device and an agent. The agent is configured to render a drug ineffective upon degradation of the at least one capsule. The at least one drug-retaining region is configured to retain one of the drug and the agent and the at least one capsule is configured to retain the other of the drug and the agent.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 22, 2010
    Applicant: PALO ALTO RESEARCH CENTER INCORPORATED
    Inventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
  • Publication number: 20100185037
    Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 22, 2010
    Applicant: Palo Alto Research Center Incorporated
    Inventors: Scott Albert Uhland, Eric Peeters, Francisco E. Torres, Philipp Helmut Schmaelzle
  • Publication number: 20090112188
    Abstract: Microchip devices are provided that include a substrate; a plurality of reservoirs in the substrate, each reservoir defining an internal volume; and a reservoir cap positioned on or in each of the reservoirs bounding the internal volume from an external environment, the reservoir cap being formed of a material that undergoes a phase change upon heating, wherein the internal volume can communicate with the external environment upon heating said reservoir cap to cause said reservoir cap to undergo a phase change and rupture.
    Type: Application
    Filed: January 5, 2009
    Publication date: April 30, 2009
    Applicant: MICROCHIPS, INC.
    Inventors: John T. Santini, JR., Michael J. Cima, Scott Albert Uhland
  • Patent number: 7473248
    Abstract: Methods are provided for controlled reservoir opening, including the steps of (a) providing a biocompatible implantable device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir. In another embodiment, the method steps include (a) implanting into a patient a biocompatible device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: January 6, 2009
    Assignee: MicroCHIPS, Inc.
    Inventors: John T. Santini, Jr., Michael J. Cima, Scott Albert Uhland
  • Publication number: 20040143236
    Abstract: Methods are provided for controlled reservoir opening, including the steps of (a) providing a biocompatible implantable device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir. In another embodiment, the method steps include (a) implanting into a patient a biocompatible device which comprises at least one substrate, a plurality of reservoirs in the substrate, reservoir caps each of which covers one of the reservoirs, and molecules sealed inside the reservoirs; and (b) selectively heating each reservoir cap in an amount effective to rupture the reservoir cap and open the reservoir.
    Type: Application
    Filed: December 29, 2003
    Publication date: July 22, 2004
    Inventors: John T. Santini, Michael J. Cima, Scott Albert Uhland